Sumitomo Mitsui Trust Group Inc. Has $252.41 Million Holdings in Cencora, Inc. $COR

Sumitomo Mitsui Trust Group Inc. reduced its holdings in Cencora, Inc. (NYSE:COR) by 8.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 803,492 shares of the company’s stock after selling 74,396 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Cencora were worth $252,409,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of COR. Kemnay Advisory Services Inc. acquired a new position in shares of Cencora in the fourth quarter valued at approximately $25,000. Oakworth Capital Inc. acquired a new stake in shares of Cencora in the fourth quarter valued at about $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp raised its position in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC bought a new stake in shares of Cencora in the 4th quarter valued at about $29,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the acquisition, the director owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.38% of the stock is owned by corporate insiders.

Cencora Stock Down 2.3%

Shares of COR opened at $302.31 on Friday. The stock’s 50-day moving average price is $277.38 and its two-hundred day moving average price is $319.09. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a market capitalization of $58.82 billion, a PE ratio of 23.18, a PEG ratio of 1.72 and a beta of 0.58. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the company posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has approved a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Morgan Stanley set a $342.00 price target on Cencora in a report on Friday, May 8th. William Blair initiated coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Bank of America increased their price objective on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. Citigroup decreased their price target on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Barclays lowered their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.